Schwan sells Roche's tepid Q3 results as "expected"
This article was originally published in Scrip
Executive Summary
Roche has kicked off the third quarter reporting pharma season with an uninspiring set of results. The Swiss company's figures suffered under the weight of the strong Swiss franc and weak sales of troubled cancer drug Avastin.